Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Running, not enrolling

Conditions studied: Diabetic Macular Edema, Diabetic Retinopathy

In brief

This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME). Participants who previously participated in the INFINITY parent study and received a single unilateral intravitreal dose of ADVM-022 are eligible for enrollment upon completion of the end of study visit in the parent study.

Key facts

Study ID

NCT05607810

Run by

Adverum Biotechnologies, Inc.

People needed

22

Starts

2022-08-10

Expected to finish

2026-04-01

Last updated by the study team

2025-04-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have participated in the ADVM-022-04 [INFINITY] (parent) study and received ADVM-022
• Must provide signed informed consent
• Must be willing and able to comply with all study procedures

You may not qualify if…

• None

Where it is running

• Adverum Clinical Site — Beverly Hills, California, United States
• Adverum Clinical Site — Reno, Nevada, United States
• Adverum Clinical Site — Philadelphia, Pennsylvania, United States
• Adverum Clinical Site — Austin, Texas, United States
• Adverum Clinical Site — Bellaire, Texas, United States
• Adverum Clinical Site — The Woodlands, Texas, United States
• Adverum Clinical Site — Arecibo, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.